menu
    • menu
    [{"orgOrder":0,"company":"Phytanix Bio","sponsor":"Protagenic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Merger","leadProduct":"PT-00114","moa":"CRH","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Phytanix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Phytanix Bio \/ Phytanix Bio","highestDevelopmentStatusID":"7","companyTruncated":"Phytanix Bio \/ Phytanix Bio"},{"orgOrder":0,"company":"Phytanix Bio","sponsor":"Protagenic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Merger","leadProduct":"PT-00114","moa":"CRH","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Phytanix Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Phytanix Bio \/ Phytanix Bio","highestDevelopmentStatusID":"7","companyTruncated":"Phytanix Bio \/ Phytanix Bio"}]

    Find Clinical Drug Pipeline Developments & Deals by Phytanix Bio

    Menu

    Phytanix Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Phytanix Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Phytanix Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PT-00114

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I/ Phase II

                            Recipient : Protagenic Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity

                            Details : The combined entity, to be called Phytanix, Inc, will bring together two pipelines focused on stress-related and CNS disorders such as PT-00114, is being evaluated for Treatment-Resistant Depression.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            May 21, 2025

                            Lead Product(s) : PT-00114

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Protagenic Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Phytanix Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Phytanix Bio

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PT-00114

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I/ Phase II

                            Recipient : Protagenic Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Protagenic & Phytanix Merge to Form Biotech With Six Neuroactive Drug Programs

                            Details : The combined entity, to be called Phytanix, Inc, will bring together two pipelines focused on stress-related and CNS disorders such as PT-00114, is being evaluated for Treatment-Resistant Depression.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            May 19, 2025

                            Lead Product(s) : PT-00114

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Protagenic Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth